Volume | 57,692 |
|
|||||
News | - | ||||||
Day High | 2.4297 | Low High |
|||||
Day Low | 2.30 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Galectin Therapeutics Inc | GALT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.38 | 2.30 | 2.4297 | 2.39 | 2.41 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
498 | 57,692 | $ 2.37 | $ 136,568 | - | 1.28 - 2.4799 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:43:02 | 25 | $ 2.40 | USD |
Galectin Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
147.2M | 61.85M | - | 0 | -38.87M | -0.63 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Galectin Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GALT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.20 | 2.4799 | 2.19 | 2.41 | 147,777 | 0.19 | 8.64% |
1 Month | 1.94 | 2.4799 | 1.895 | 2.17 | 106,553 | 0.45 | 23.20% |
3 Months | 1.68 | 2.4799 | 1.59 | 1.98 | 72,751 | 0.71 | 42.26% |
6 Months | 1.83 | 2.4799 | 1.555 | 1.94 | 68,756 | 0.56 | 30.60% |
1 Year | 1.93 | 2.4799 | 1.28 | 1.82 | 61,217 | 0.46 | 23.83% |
3 Years | 2.13 | 5.70 | 1.02 | 3.02 | 484,441 | 0.26 | 12.21% |
5 Years | 4.65 | 5.70 | 1.02 | 3.05 | 401,277 | -2.26 | -48.60% |
Galectin Therapeutics Description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis. |